Studies on molecular mechanisms of approved systemic treatments with tyrosine-kinase-inhibitors (TKI), sorafenib and regorafenib, for patients with advanced HCC disease have been shown to act in part through an NF-κB-dependent mechanism: Sorafenib inhibits expressions of matrix metalloproteinase-9 (MMP9) and vascular endothelial growth factor (VEGF) by impairing the ERK/NF-κB-pathway in HCC cells [95,96]. This evidence concerns the gene MMP9 and hepatocellular carcinoma.